Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy?

Sergio Rizzo, Giuseppe Bronte, Daniele Fanale, Lidia Corsini, Nicola Silvestris, Daniele Santini, Gaspare Gulotta, Viviana Bazan, Nicola Gebbia, Fabio Fulfaro, Antonio Russo

Research output: Contribution to journalArticle

Abstract

An important molecular target for metastatic CRC treatment is the epidermal growth factor receptor (EGFR). Many potential biomarkers predictive of response to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) have been retrospectively evaluated, including EGFR activation markers and EGFR ligands activation markers. With regard to the 'negative predictive factors'responsible for primary or intrinsic resistance to anti-EGFR antibodies a lot of data are now available. Among these, KRAS mutations have emerged as a major predictor of resistance to panitumumab or cetuximab in the clinical setting and several studies of patients receiving first and subsequent lines of treatment have shown that those with tumors carrying KRAS mutations do not respond to EGFR-targeted monoclonal antibodies or show any survival benefit from such treatments. The role of B-RAF mutations, mutually exclusive with KRAS mutations, in predicting resistance to anti-EGFR mAbs is not yet consolidated. It therefore appears that BRAF mutations may play a strong negative prognostic role and only a slight role in resistance to anti-EGFR Abs.

Original languageEnglish
JournalCancer Treatment Reviews
Volume36
Issue numberSUPPL. 3
DOIs
Publication statusPublished - Nov 2010

Keywords

  • Driver mutations
  • EGFR
  • KRAS
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy?'. Together they form a unique fingerprint.

  • Cite this

    Rizzo, S., Bronte, G., Fanale, D., Corsini, L., Silvestris, N., Santini, D., Gulotta, G., Bazan, V., Gebbia, N., Fulfaro, F., & Russo, A. (2010). Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treatment Reviews, 36(SUPPL. 3). https://doi.org/10.1016/S0305-7372(10)70021-9